Uncategorized

OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy

OBI Pharma, Inc. announced preclinical data demonstrating significant synergistic effects of OBI-999 and pembrolizumab in four different cancer models, as well as the potent antitumor effect of a chimeric antigen receptor T-cell immunotherapy targeting Globo H.

OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy Read More »

GC Genome Announces Publication Demonstrating Feasibility of Liquid Biopsy Technology to Predict Radiation Therapy Response in Solid Tumors

GC Genome Corporation announced the publication of a new study in Radiation Oncology Journal, which demonstrates the feasibility of cell-free DNA monitoring to predict treatment response and detect minimal residual disease after radiation therapy in solid tumor patients using I-score, a tool for calculating genomic instabilities developed by GC Genome.

GC Genome Announces Publication Demonstrating Feasibility of Liquid Biopsy Technology to Predict Radiation Therapy Response in Solid Tumors Read More »

Syncell Showcases Pioneering Microscopy-Guided Subcellular Protein Scooping Technology at the AACR Annual Meeting 2023

Syncell, a biotech company pioneering in platforms for hypothesis-free spatial proteomics, will be exhibiting and presenting a poster at the AACR Annual Meeting 2023 in Orlando, FL. Syncell’s Microscoop technology enables microscopy-guided subcellular protein scooping in ultra-content powered by AI to collect enough proteins for subsequent spatial proteomic identification.

Syncell Showcases Pioneering Microscopy-Guided Subcellular Protein Scooping Technology at the AACR Annual Meeting 2023 Read More »

YDS Pharmatech’s New Generative Diffusion Model Significantly Improves Structure-Based PROTAC Optimization and Ternary Interaction Analysis; Presentation at Drug Discovery Chemistry 2023 Conference

A groundbreaking study by a team of scientists at YDS Pharmatech, Inc. has introduced an innovative Generative Diffusion Model for sampling ensembles of degrader-induced ternary interactions, enabling a more effective approach to structure-based optimization of Proteolysis Targeting Chimeras.

YDS Pharmatech’s New Generative Diffusion Model Significantly Improves Structure-Based PROTAC Optimization and Ternary Interaction Analysis; Presentation at Drug Discovery Chemistry 2023 Conference Read More »

Scroll to Top